Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

INTRODUCTION: Turoctocog alfa pegol (N8‐GP) is a site‐specific, 40 kDa glycoPEGylated recombinant factor VIII (FVIII) product with an extended half‐life. The comprehensive main phase of the pivotal pathfinder 2 trial showed N8‐GP dosed every 4 days (Q4D) provided favourable safety and efficacy for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Curry, Nicola, Albayrak, Canan, Escobar, Miguel, Andre Holme, Pål, Kearney, Susan, Klamroth, Robert, Misgav, Mudi, Négrier, Claude, Wheeler, Allison, Santagostino, Elena, Shima, Midori, Landorph, Andrea, Tønder, Sidsel Marie, Lentz, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850405/
https://www.ncbi.nlm.nih.gov/pubmed/30817066
http://dx.doi.org/10.1111/hae.13712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850405/
https://www.ncbi.nlm.nih.gov/pubmed/30817066
http://dx.doi.org/10.1111/hae.13712

Ejemplares similares